Methods and compositions to detect mutations in plasma using exosomal RNA and cell free DNA from non-small cell lung cancer patients
The present invention relates generally to methods and kits for detecting one or more biomarkers, such as an Epidermal Growth Factor Receptor (EGFR) mutation, e.g., T790M mutation, L858R mutation, one or more exon19 insertions and/or one or more exon19 deletions in the EGFR gene, in a biological sample to aid in diagnosis, prognosis, monitoring, or therapy selection for a disease such as, for example, cancer. The methods and kits are useful in aiding in diagnosis, prognosis, monitoring, or therapy selection for lung cancer, e.g., non-small cell lung cancer (NSCLC).
1. A method for treating lung cancer in a subject in need thereof comprising:
(a) extracting RNA and DNA from at least one microvesicle isolated from a plasma sample from the subject;
(b) isolating at least one circulating nucleic acid from the plasma sample;
(c) performing a reverse transcription reaction using the RNA and DNA extracted from the at least one microvesicle and the at least one circulating nucleic acid;
(d) performing a pre-amplification reaction of the products of step (c), wherein the preamplification reaction step is a multiplex pre-amplification reaction that comprises a wildtype blocker for exon 20 of the Epidermal Growth Factor Receptor (EGFR) gene;
(e) detecting the amount of at least one Epidermal Growth Factor Receptor (EGFR) variant and the amount of exon 7 of the EGFR gene in the products of step (d) using quantitative PCR (qPCR), wherein the at least one EGFR variant is EGFR T790M ;
(f) comparing each amount detected in step (e) to a corresponding pre-defined cutoff threshold to determine the presence or the absence of the EGFR variant in the plasma sample; and
(g) administering to the subject at least one anti-cancer therapy when the EGFR variant is determined to be present in the plasma sample.
2. The method of claim 1 , wherein the at least one circulating nucleic acid comprises cell-free DNA, cell-free RNA, necrotic DNA, necrotic RNA or any combination thereof.
3. The method of claim 1 , further comprising prior to step (a), adding a known quantity of at least one control nucleic acid to the plasma sample, and wherein step (e) comprises detecting the amount of the at least one control nucleic acid.
4. The method of claim 1 , wherein the wild type blocker comprises a hydrophobic nucleic acid, a bridge nucleic acid, a peptide nucleic acid, an oligonucleotide comprising a 3′ end terminator or any combination thereof.
5. The method of claim 1 , wherein the qPCR comprises a mutant-specific amplification system, a mutation-biased amplification system or any combination thereof.
6. The method of claim 1 , wherein the qPCR comprises an Amplification Refractory Mutation system (ARMS).
7. The method of claim 6 , wherein the ARMS comprises at least one primer comprising at least one modified nucleotide, at least one primer comprising at least one modified base, at least one primer comprising at least one modified sequence, at least one probe comprising at least one modified nucleotide, at least one probe comprising at least one modified base, at least one probe comprising at least one modified sequence or any combination thereof.
8. The method of claim 7 , wherein the ARMS comprises at least one primer comprising 2-aminopurine, 8-amino-2′-deoxyadenosine, trimetroxystilbene, C-5 propynyl-deoxycytidine, C-5 propynyl-deoxyuridine, 2-amino-2′-deoxyadenosine-5′-triphosphate, 2,6-diaminopurine (2-amino-dA), inverted dT, inverted dideoxy-T, hydroxymethyl dC, iso-dC, 5-methyl dC, aminoethyl-phenoxazine-deoxycytidine, locked nucleic acids, at least one mismatched base or any combination thereof.
9. The method of claim 1 , wherein the lung cancer is non-small cell lung cancer.
10. The method of claim 1 , wherein the anti-cancer therapy comprises administering to the subject at least one therapeutically effective amount of an EGFR inhibitor.
11. The method of claim 10 , wherein the EGFR inhibitor is gefitinib, erlotinib, lapatinib, cetuximab, panitumumab, vandetanib, neratinib, necitumumab, osimertinib or any combination thereof.
12. The method of claim 1 , wherein the anti-cancer therapy comprises administering to the subject at least one therapeutically effective amount of a second generation tyrosine kinase EGFR inhibitor, a third generation tyrosine kinase EGFR inhibitor, an EGFR T790M -targeting compound, an EGFR L858R -targeting compound, a compound that targets EGFR comprising at least one exon 19 insertion, a compound that targets EGFR comprising at least one exon 19 deletion or any combination thereof.